Page last updated: 2024-10-15
glucosepane
Description
glucosepane: a protein cross-link; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 135565852 |
SCHEMBL ID | 22559684 |
MeSH ID | M0538476 |
Synonyms (8)
Synonym |
---|
glucosepane |
(2s)-2-amino-6-((6r,7s)-2-(((s)-4-amino-4-carboxybutyl)amino)-6,7-dihydroxy-6,7,8,8a-tetrahydroimidazo(4,5-b)azepin-4(5h)-yl)hexanoic acid |
glucosepan |
257290-23-6 |
66K23JT22H , |
unii-66k23jt22h |
DTXSID80894863 |
SCHEMBL22559684 |
Research Excerpts
Overview
Glucosepane is a novel AGE marker of diabetic complications that is robustly associated with nephropathic, retinopathic and neuropathic outcomes. It could be one mediator of these complications with possible diagnostic implications.
Excerpt | Reference |
---|---|
"Glucosepane is a structurally complex protein posttranslational modification that is believed to exist in all living organisms. " | ( Concise total synthesis of glucosepane. Draghici, C; Spiegel, DA; Wang, T, 2015) |
"Glucosepane is a collagen cross-linking advanced glycation end product; the structural and mechanical effects of glucosepane are still the subjects of much debate." | ( Computational study of glucosepane-water and hydrogen bond formation: an electron topology and orbital analysis. Birch, HL; Bozec, L; de Leeuw, NH; Nash, A; Saßmannshausen, J, 2017) |
"Glucosepane is a novel AGE marker of diabetic complications that is robustly associated with nephropathic, retinopathic and neuropathic outcomes despite adjustment for A1c, suggesting that it could be one mediator of these complications with possible diagnostic implications." | ( The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. Cleary, PA; Genuth, S; Lachin, JM; Monnier, VM; Sell, DR; Strauch, C; Sun, W, ) |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (23)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (4.35) | 29.6817 |
2010's | 19 (82.61) | 24.3611 |
2020's | 3 (13.04) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (12.50%) | 5.53% |
Reviews | 3 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (75.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |